Advanced tests like fluorescence in situ hybridization (FISH) help determine prognosis for lymphoma/leukemia patients. In this instance, CLL is detected.
Molecular diagnostics provide precise information about a patient’s cancer, and can help doctors decide on the best treatment. The rapid increase in the incidence of cancer worldwide, together with advances in specific cancer-focused biopharmaceuticals is driving significant demand for molecular diagnostics. The global demand for cancer-profiling products and services is predicted to grow from $15 billion in 2009 to an estimated $47 billion by 2015*.
The combination of Clarient’s and GE Healthcare’s capabilities in disease diagnosis will offer substantial clinical benefits to patients, pathologists and oncologists, helping to lower costs and improve the quality of healthcare globally.
Clarient provides pathologists and oncologists with access to key diagnostic tests that shed light on the complex nature of various cancers. Clarient is focused on developing novel, proprietary diagnostic markers and tests for the profiling of breast, prostate, lung, colon and blood-based cancers, to help clinicians make informed decisions on how best to treat their patients. Given the increasing importance of more targeted cancer diagnostics, Clarient is well positioned to bring differentiated, added-value molecular diagnostic products and services to market.
GE Healthcare is a world-class provider of diagnostic technologies, information technology and life science tools. Its broad range of products and services enable healthcare providers to better diagnose and monitor the treatment of a wide range of cancers. This transaction complements GE Healthcare’s recent expansion in its capabilities and offerings in cancer diagnostics and in pathology, including strategic relationships with Eli Lilly and Company and the University of Pittsburgh Medical Center (UPMC) in the areas of molecular and digital pathology, respectively. Clarient will bring new, complementary capabilities to GE Healthcare. Going forward, GE Healthcare is focused on developing integrated diagnostic solutions for cancer, and other disease states, that combine selected in vivo, in vitro and informatics capabilities.
Important Additional Information
The tender offer described in this webpage has not yet commenced, and this information is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, General Electric Company will cause its indirect, wholly-owned subsidiary, Crane Merger Sub, Inc., to file a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (“SEC”). Potential investors and Clarient stockholders are strongly advised to read the tender offer statement (which will include an offer to purchase, letter of transmittal and related tender offer documents) and the related solicitation/recommendation statement on Schedule 14D-9 that will be filed by Clarient with the SEC because they will contain important information about the tender offer. These documents will be available at no charge on the SEC’s website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents (once they become available) may be obtained free of charge by directing a request to Crane Merger Sub, Inc. at GE Healthcare, 9900 W Innovation Drive, Wauwatosa, WI 53226, Attention: “Corporate Counsel – Business Development”. Potential investors and Clarient stockholders may also read and copy any reports, statements and other information filed by GE, Crane Merger Sub or Clarient with the SEC, at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 or visit the SEC’s website for further information on its public reference room.